Cargando…

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

INTRODUCTION: Nirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower respiratory tract infection in infants for the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brady, Tyler, Cayatte, Corinne, Roe, Tiffany L., Speer, Scott D., Ji, Hong, Machiesky, LeeAnn, Zhang, Tianhui, Wilkins, Deidre, Tuffy, Kevin M., Kelly, Elizabeth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600457/ https://www.ncbi.nlm.nih.gov/pubmed/37901217 http://dx.doi.org/10.3389/fimmu.2023.1283120

Ejemplares similares

2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
por: Morehouse, Christopher A, et al.
Publicado: (2023)

94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants
por: Abram, Michael E, et al.
Publicado: (2022)

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
por: Wilkins, Deidre, et al.
Publicado: (2023)

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
por: Ahani, Bahar, et al.
Publicado: (2023)

Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
por: Zhaori, Getu
Publicado: (2023)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
por: Wilkins, Deidre, et al.
Publicado: (2023)

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
por: Jones, Jefferson M., et al.
Publicado: (2023)

Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States
por: Gomez, Gabriela B, et al.
Publicado: (2022)

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023)

Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies
por: Dippel, Andrew, et al.
Publicado: (2022)

89. The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study
por: Faust, Saul N, et al.
Publicado: (2023)

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
por: Domachowske, Joseph B, et al.
Publicado: (2023)

Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding
por: Lu, Xiaojun, et al.
Publicado: (2020)

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis
por: Turalde-Mapili, Maria Wilma R., et al.
Publicado: (2023)

Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper
por: Esposito, Susanna, et al.
Publicado: (2021)

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
por: Hammitt, Laura, et al.
Publicado: (2021)

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
por: Brady, Tyler, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
por: Tuffy, Kevin M, et al.
Publicado: (2023)

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
por: Simões, Eric A F, et al.
Publicado: (2023)

Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity
por: Goldberg, Benjamin S., et al.
Publicado: (2021)

The role of Fc–FcγR interactions in IgG-mediated microbial neutralization
por: Bournazos, Stylianos, et al.
Publicado: (2015)

The role of the complement and the FcγR system in the pathogenesis of arthritis
por: Solomon, Samuel, et al.
Publicado: (2005)

Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model
por: Voirin, Nicolas, et al.
Publicado: (2021)

Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice
por: Cayatte, Corinne, et al.
Publicado: (2017)

Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
por: van Erp, Elisabeth A., et al.
Publicado: (2019)

Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials
por: Broadbent, Lindsay, et al.
Publicado: (2015)

Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
por: Mori, Filippo, et al.
Publicado: (2021)

Post-extubation stridor in Respiratory Syncytial Virus bronchiolitis: Is there a role for prophylactic dexamethasone?
por: Veldhoen, Esther S., et al.
Publicado: (2017)

Antibody and complement-dependent viral neutralization
por: Cooper, Neil R., et al.
Publicado: (1979)

Contribution of Fcγ Receptor-Mediated Immunity to the Pathogenesis Caused by the Human Respiratory Syncytial Virus
por: Acevedo, Orlando A., et al.
Publicado: (2019)

Fragment-based identification of determinants of conformational and spectroscopic change at the ricin active site
por: Carra, John H, et al.
Publicado: (2007)

Dengue Virus Neutralization in Cells Expressing Fc Gamma Receptors
por: Chawla, Tanu, et al.
Publicado: (2013)

Illuminating the Fc dependence of SARS-CoV-2 neutralization
por: González, Joseph C., et al.
Publicado: (2021)

Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins
por: Schepp, Rutger M., et al.
Publicado: (2019)

Fcγ receptors complement interaction: new aspects in pathogenesis and treatment of vasculititis
por: Schmidt, RE
Publicado: (2003)

Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein
por: Mader, Simone, et al.
Publicado: (2023)

A morphological transformation in respiratory syncytial virus leads to enhanced complement deposition
por: Kuppan, Jessica P, et al.
Publicado: (2021)

Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination
por: Wilkins, Deidre, et al.
Publicado: (2022)

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
por: Kieffer, Alexia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9m3sj1pb2t8j80cp3d8a4k82b8